Atrys Health (XMAD:ATRY) GF Score: 68/100 (As of Jun. 29, 2026) — 21% Above Median


XMAD:ATRY Atrys Health SA XMAD:ATRY
68 GF Score
Price €2.58
GF Value €3.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health GF Score?

Atrys Health XMAD:ATRY +0.19% 68 GF Score is 68 as of Jun. 29, 2026, which is 21% above its 10-year median of 56.00. GuruFocus rates XMAD:ATRY with a GF Score™ of 68/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Atrys Health has the GF Score of 68, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 2/10
2. Profitability Rank : 3/10
3. Growth Rank : 7/10
4. GF Value Rank : 8/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Atrys Health might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Atrys Health  (XMAD:ATRY) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Atrys Health GF Score Related Terms

XMAD:ATRY vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Atrys Health's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrys Health GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's GF Score distribution charts can be found below:

* The bar in red indicates where Atrys Health's GF Score falls into.


XMAD:ATRY
68GF Score
Atrys Health SA XMAD:ATRY
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 68 mean?
Atrys Health (XMAD:ATRY) has a GF Score of 68 as of Jun. 29, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Atrys Health and its competitors. This is 21% above median its historical median of 56.00. Over the past decade, Atrys Health's GF Score has ranged from 11.00 to 80.00.
Is Atrys Health's GF Score too high?
Atrys Health's current GF Score of 68 is 21% above median its 10-year median of 56.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 80.00. Overall, Atrys Health has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's GF Score compare to VRTX and REGN?
Atrys Health's GF Score of 68 can be compared against companies in the Biotechnology industry. Historically, Atrys Health's own GF Score has ranged from 11.00 to 80.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Atrys Health and its competitors. Atrys Health's current GF Score is 68, which is 21% above median its own 10-year median of 56.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.58 — trading 17% below its estimated fair value. The current GF Score is 68, which is 21% above median its 10-year median of 56.00. Atrys Health's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current GF Score is 68 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.58 is trading 17% below its estimated GF Value™ of €3.11. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • GF Score: 68 (21% above median its 10-year median of 56.00)
  • GF Value™: €3.11 vs. price of €2.58 (17% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score

Get the complete analysis for XMAD:ATRY

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.58
Price
€3.11
GF Value